Trial Profile
Single-dose fosaprepitant versus 5-day aprepitant for the prevention of nausea and vomiting induced by cisplatin-based chemotherapy in cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Aprepitant
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 18 Oct 2016 New trial record